Screener
Adaptive Biotechnologies ADPT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| (unaudited) | ||
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $77,581 | $70,495 |
| Short-term marketable securities (amortized cost of $140,762 and $156,246, respectively) | 140,753 | 156,485 |
| Accounts receivable, net | 48,315 | 50,365 |
| Inventory | 11,206 | 9,820 |
| Prepaid expenses and other current assets | 13,952 | 13,020 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's cash & equivalents?
- Adaptive Biotechnologies (ADPT) reported cash & equivalents of $77.58M in Q1 2026.
- How has Adaptive Biotechnologies's cash & equivalents changed year-over-year?
- Adaptive Biotechnologies's cash & equivalents increased by 53.2% year-over-year, from $50.65M to $77.58M.
- What is the long-term trend for Adaptive Biotechnologies's cash & equivalents?
- Over 5 years (2020 to 2025), Adaptive Biotechnologies's cash & equivalents has grown at a -10.6% compound annual growth rate (CAGR), from $123.44M to $70.5M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Adaptive Biotechnologies's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude